(Q45967631)

18 December 2017

title

Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. (English)

1 reference

18 December 2017

0 references

V Ionut

1

1 reference

18 December 2017

K Hucking

series ordinal

2

1 reference

18 December 2017

I F Liberty

series ordinal

3

1 reference

18 December 2017

R N Bergman

series ordinal

4

1 reference

18 December 2017

language of work or name

1 reference

14 April 2005

1 reference

18 December 2017

published in

Diabetologia

1 reference

18 December 2017

volume

48

1 reference

18 December 2017

issue

5

1 reference

18 December 2017

page(s)

967-975

1 reference

18 December 2017

https://scigraph.springernature.com/pub.10.1007/s00125-005-1709-3

exact match

0 references

cites work

Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-005-1709-3

Enteral infusion of glucose at rates approximating EGP enhances glucose disposal but does not cause hypoglycemia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-005-1709-3

Distribution and molecular forms of glucagon-like peptide in the dog

21 January 2018

1 reference

12 December 2020

Is glucagon-like peptide 1 an incretin hormone?

1 reference

12 December 2020

Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.

1 reference

12 December 2020

Portal vein afferents are critical for the sympathoadrenal response to hypoglycemia

1 reference

12 December 2020

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

1 reference

12 December 2020

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

12 December 2020

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

1 reference

12 December 2020

Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

1 reference

12 December 2020

GLP-1 does not acutely affect insulin sensitivity in healthy man

1 reference

12 December 2020

Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms

1 reference

12 December 2020

Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.

1 reference

12 December 2020

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

12 December 2020

Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic.

1 reference

12 December 2020

Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs

1 reference

12 December 2020

The role of liver glucosensors in the integrated sympathetic response induced by deep hypoglycemia in dogs.

1 reference

12 December 2020

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

1 reference

12 December 2020

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

1 reference

12 December 2020

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

1 reference

12 December 2020

Accurate measurement of endogenous insulin secretion does not require separate assessment of C-peptide kinetics

1 reference

12 December 2020

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential

1 reference

12 December 2020

Hierarchy of physiological responses to hypoglycemia: relevance to clinical hypoglycemia in type I (insulin dependent) diabetes mellitus

1 reference

12 December 2020

The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein

1 reference

12 December 2020

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

1 reference

12 December 2020

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig

1 reference

12 December 2020

Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs.

1 reference

12 December 2020

The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor

1 reference

12 December 2020

Importance of Hepatic Glucoreceptors in Sympathoadrenal Response to Hypoglycemia

1 reference

12 December 2020

The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones

1 reference

12 December 2020

Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization.

1 reference

12 December 2020

Biological actions and therapeutic potential of the glucagon-like peptides

1 reference

12 December 2020

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

1 reference

12 December 2020

Alpha- and beta-cell responses to small changes in plasma glucose in the conscious dog.

1 reference

12 December 2020

Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men

1 reference

12 December 2020

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

1 reference

12 December 2020

Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes

1 reference

12 December 2020

Transendothelial insulin transport is not saturable in vivo. No evidence for a receptor-mediated process

1 reference

12 December 2020

Enteral Enhancement of Glucose Disposition by Both Insulin-Dependent and Insulin-Independent Processes: A Physiological Role of Glucagon-Like Peptide I

1 reference

12 December 2020

Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1

1 reference

12 December 2020

Minireview: the glucagon-like peptides

1 reference

12 December 2020

Unlike mice, dogs exhibit effective glucoregulation during low-dose portal and peripheral glucose infusion

1 reference

12 December 2020

10.1007/S00125-005-1709-3

Identifiers

DOI

1 reference

18 December 2017

Dimensions Publication ID

0 references

1 reference

18 December 2017